Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 10/14/23 01:15:00 on US and Canada Markets.
2023-10-14 13:15:00 ET Investors have very different opinions on Wayfair (NYSE: W) and RH (NYSE: RH) stocks right now. Both companies compete in the home furnishings industry, which is contracting today. But Wayfair shares are surging, while RH is in negative territory for 2...
2023-10-14 13:15:00 ET Investors have very different opinions on Wayfair (NYSE: W) and RH (NYSE: RH) stocks right now. Both companies compete in the home furnishings industry, which is contracting today. But Wayfair shares are surging, while RH is in negative territory for 2...
2023-10-14 13:11:00 ET Warren Buffett loves a good dividend stock. What he loves even more, though, is a stock that can consistently increase its dividend over time. Case in point: Buffett first purchased shares of Coca-Cola (NYSE: KO) for Berkshire Hathaway 's (NYSE: BRK....
2023-10-14 12:30:00 ET As computing technology advances, it has become increasingly clear in recent years that tighter integration between semiconductor and software development is needed. The surge in artificial intelligence (AI) activity in 2023 embodies this. As Nvidia (NASDAQ: NVD...
2023-10-14 12:30:00 ET As computing technology advances, it has become increasingly clear in recent years that tighter integration between semiconductor and software development is needed. The surge in artificial intelligence (AI) activity in 2023 embodies this. As Nvidia (NASDAQ: NVD...
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches – - IND and initiation of clinical trial planned in 2H 2024 - WALTHAM, Mass. and BOULDER, Colo...
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference ...
Initial results from BDTX-1535 dose escalation show durable activity in patients with NSCLC across heterogeneous EGFR mutation subtypes No new safety or tolerability signal reported across all three active once daily doses of 100mg, 200mg and 300mg Initial NSCLC exp...
Avutometinib + Sotorasib Combination Demonstrated Preliminary Efficacy with Confirmed Responses in both KRAS G12C Inhibitor Resistant and Naïve Patients No New Safety Signals Observed in Combination; Most Treatment-Related Adverse Events Mild to Moderate Enrollment of Patient...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head and neck squamous cell carcinoma (Clinicaltrials.gov identifier NCT04555837) at the 20...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
-1.34%Change Percent:
KULR Technology Group Inc. Company Name:
KULR Stock Symbol:
NYSE Market: